REVB

Revelation

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 1

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About REVB

Revelation Biosciences, Inc.

A clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and infectious diseases

Industry

Biological Technology

Established Date

11/20/2019

Listing Date

11/17/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.revbiosciences.com

Security Type

Common stock

Office address

4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122

Business

Introduction

Revelation Biosciences, Inc., a Delaware corporation, was founded on November 20, 2019. The company is a clinical-stage life sciences company focused on developing immunotherapies for the prevention and treatment of diseases. Revelation has several product candidates in development. REVTx-99 is the primary therapeutic candidate and is an intranasal immunomodulator for the prevention or treatment of infections caused by various respiratory viruses. REVTx-99 is also being developed for other indications such as allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjuvant that can be used in combination with an intramuscular vaccine for more complete immunity. Revelation is also developing REVDx-501, a rapid home diagnostic tool that can be used to detect any respiratory viral infection without the need for specialized instruments.

Company Financials

EPS

REVB has released its 2024 Q4 earnings. EPS was reported at -4.98, versus the expected -10.32, beating expectations. The chart below visualizes how REVB has performed over recent quarters, highlighting trends in earnings surprises.